The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: The Enroute⊕ Study

BMC Surgery

Volumn 11, Issue , 2011, Pages

  Lips, Daniel J ^a   Koebrugge, Boukje ^a,b   Jan Liefers, Gerrit ^b   Van De Linden, Johannes C ^a   Smit, Vincent T H B M ^b   Pruijt, Hans F M ^a   Putter, Hein ^b   Van De Velde, Cornelis J H ^b   Bosscha, Koop ^a  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; CLINICAL PROTOCOLS; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 79955756287     PISSN: None     EISSN: 14712482     Source Type: Journal    
DOI: 10.1186/1471-2482-11-11     Document Type: Article

References (34)

1. Increasing incidence and decreasing mortality of colorectal cancer due to marked cohort effects in southern Netherlands. LN van Steenbergen VE Lemmens MJ Louwman JW Straathof JW Coebergh, Eur J Cancer Prev 2009 18 145 152 10.1097/CEJ.0b013e32831362e7 19337062
2. Guideline 'Colon cancer'. Association of Comprehensive Cancer Centres, 2008 http://www.oncoline.nl Ref Type: Electronic Citation
3. Is occult lymph node disease in colorectal cancer patients clinically significant? A review of the relevant literature. DG Nicastri JT Doucette TE Godfrey SJ Hughes, J Mol Diagn 2007 9 563 571 10.2353/jmoldx.2007.070032 17916603 (Pubitemid 350158413)
4. The prognostic effect of micrometastases in previously staged lymph node negative (N0) colorectal carcinoma: a meta-analysis. D Iddings A Ahmad D Elashoff A Bilchik, Ann Surg Oncol 2006 13 1386 1392 10.1245/s10434-006-9120-y 17009147 (Pubitemid 44749649)
5. Surgical quality and nodal ultrastaging is associated with long-term disease-free survival in early colorectal cancer: an analysis of 2 international multicenter prospective trials. A Bilchik A Nissan Z Wainberg P Shen M McCarter M Protic,, et al. Ann Surg 2010 252 467 474 20739847
6. Improving staging accuracy in colon and rectal cancer by sentinel lymph node mapping: A comparative study. ES van der Zaag CJ Buskens N Kooij H Akol HM Peters WH Bouma,, et al. Eur J Surg Oncol 2009 35 1065 1070 19261431
7. Ex vivo sentinel lymph node "mapping" in colorectal cancer. PM van Schaik JC van der Linden MF Ernst WA Gelderman K Bosscha, Eur J Surg Oncol 2007 33 1177 1182 17449218 (Pubitemid 350091351)
8. Prospective randomized study comparing sentinel lymph node evaluation with standard pathologic evaluation for the staging of colon carcinoma: results from the United States Military Cancer Institute Clinical Trials Group Study GI-01. A Stojadinovic A Nissan M Protic CF Adair D Prus S Usaj,, et al. Ann Surg 2007 245 846 857 10.1097/01.sla.0000256390.13550.26 17522508 (Pubitemid 46809284)
9. Validation of ex vivo lymphatic mapping in hematoxylin-eosin node-negative carcinoma of the colon and rectum. JH Wong DS Johnson T Namiki P Tauchi-Nishi, Ann Surg Oncol 2004 11 772 777 10.1245/ASO.2004.11.026 15249341 (Pubitemid 40486692)
10. Quantitative RT-PCR detection of tumor cells in sentinel lymph nodes isolated from colon cancer patients with an ex vivo approach. O Nordgard S Oltedal H Korner OG Aasprong K Tjensvoll B Gilje,, et al. Ann Surg 2009 249 602 607 10.1097/SLA.0b013e31819ec923 19300229
11. Factors affecting false-negative rates on ex vivo sentinel lymph node mapping in colorectal cancer. A Sommariva PM Donisi B Gnocato R Vianello PV Stracca G Zaninotto, Eur J Surg Oncol 2010 36 2 130 4 19615850
12. Micrometastases or isolated tumor cells and the outcome of breast cancer. BM de CH van Deurzen JA van Dijck GF Borm PJ van Diest EM Adang,, et al. N Engl J Med 2009 361 653 663 10.1056/NEJMoa0904832 19675329
13. The necessity of chemotherapy in T3N0M0 colon cancer without risk factors. HR Yun HC Kim WY Lee YB Cho SH Yun HK Chun, Am J Surg 2009 198 354 358 10.1016/j.amjsurg.2008.09.027 19716883
14. Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based setting. M Morris C Platell K McCaul M Millward HG van E Bayliss,, et al. Int J Colorectal Dis 2007 22 887 895 10.1007/s00384-006-0262-y 17235506 (Pubitemid 46952037)
15. Association of Comprehensive Cancer Centres. Association of Comprehensive Cancer Centers. 2010 http://www.vikc.net Ref Type: Electronic Citation
16. Adjuvant therapy for completely resected stage II colon cancer. A Figueredo ME Coombes S Mukherjee, Cochrane Database Syst Rev 2008 D005390
17. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999 17 1356 63 10334519
18. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? S Gill CL Loprinzi DJ Sargent SD Thome SR Alberts DG Haller,, et al. J Clin Oncol 2004 22 1797 1806 10.1200/JCO.2004.09.059 15067028 (Pubitemid 41095169)
19. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. JB O'Connell MA Maggard CY Ko, J Natl Cancer Inst 2004 96 1420 1425 10.1093/jnci/djh275 15467030 (Pubitemid 39429665)
20. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. T Andre C Boni L Mounedji-Boudiaf M Navarro J Tabernero T Hickish,, et al. N Engl J Med 2004 350 2343 2351 10.1056/NEJMoa032709 15175436 (Pubitemid 38702845)
21. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). DG Haller J Tabernero J Maroun J de Braud T Price E van cutsem,, et al. Eur J Cancer Supplements 2009 7 4
22. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. BG Taal TH Van FA Zoetmulder, Br J Cancer 2001 85 1437 1443 10.1054/bjoc.2001.2117 11720425 (Pubitemid 34001570)
23. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. K Koyanagi AJ Bilchik S Saha RR Turner D Wiese M McCarter,, et al. Clin Cancer Res 2008 14 7391 7396 10.1158/1078-0432.CCR-08-0290 19010855
24. Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. AJ Bilchik M DiNome S Saha RR Turner D Wiese M McCarter,, et al. Arch Surg 2006 141 527 533 10.1001/archsurg.141.6.527 16785352
25. Comparative analysis of nodal upstaging between colon and rectal cancers by sentinel lymph node mapping: a prospective trial. S Saha KM Monson A Bilchik T Beutler AG Dan E Schochet,, et al. Dis Colon Rectum 2004 47 1767 1772 10.1007/s10350-004-0661-5 15622567 (Pubitemid 40064419)
26. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. S Saha R Seghal M Patel K Doan A Dan A Bilchik,, et al. Am J Surg 2006 191 305 310 10.1016/j.amjsurg.2005.10.028 16490536 (Pubitemid 43265995)
27. Sentinel node biopsy for the individualization of surgical strategy for cure of early-stage colon cancer. RA Cahill A Bembenek S Sirop DF Waterhouse W Schneider J Leroy,, et al. Ann Surg Oncol 2009 16 2170 2180 10.1245/s10434-009- 0510-9 19472012
28. Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. AE Bembenek R Rosenberg E Wagler S Gretschel A Sendler JR Siewert,, et al. Ann Surg 2007 245 858 863 10.1097/01.sla.0000250428.46656.7e 17522509 (Pubitemid 46809285)
29. The sentinel node procedure in colon carcinoma: a multi-centre study in The Netherlands. W Kelder AE Braat A Karrenbeld JA Grond JE De Vries JW Oosterhuis,, et al. Int J Colorectal Dis 2007 22 1509 1514 10.1007/s00384-007- 0351-6 17622543 (Pubitemid 47543343)
30. The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer. M Davies PJ Arumugam VI Shah A Watkins MA Roger ND Carr,, et al. Clin Transl Oncol 2008 10 175 179 10.1007/s12094-008-0176-y 18321821
31. Timing of relapse and outcome after curative resection for colorectal cancer: a Japanese multicenter study. H Kobayashi H Mochizuki T Morita K Kotake T Teramoto S Kameoka,, et al. Dig Surg 2009 26 249 255 10.1159/000226868 19571539
32. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. ED Saad A Katz PM Hoff M Buyse, Ann Oncol 2009 21 1 7 12 19901012
33. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. DJ Sargent HS Wieand DG Haller R Gray JK Benedetti M Buyse,, et al. J Clin Oncol 2005 23 8664 8670 10.1200/JCO.2005.01.6071 16260700 (Pubitemid 46211509)
34. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. GA De J Hubbard Q Shi MJ O'Connell M Buyse J Benedetti,, et al. J Clin Oncol 2010 28 460 465 10.1200/JCO.2009.23.1407 20008641